Ulrich Germing mainly investigates Internal medicine, Myelodysplastic syndromes, Surgery, Oncology and Leukemia. His Internal medicine research includes themes of Gastroenterology and Pathology. The study incorporates disciplines such as Survival rate, Retrospective cohort study and Pediatrics in addition to Myelodysplastic syndromes.
His Surgery study integrates concerns from other disciplines, such as Azacitidine, Multivariate analysis and Risk factor. His studies in Oncology integrate themes in fields like Survival analysis, Clinical trial, Proportional hazards model and Immunophenotyping. His work in the fields of Leukemia, such as Myelogenous, overlaps with other areas such as Context.
His primary scientific interests are in Internal medicine, Myelodysplastic syndromes, Oncology, Gastroenterology and Bone marrow. He interconnects Surgery and Immunology in the investigation of issues within Internal medicine. Ulrich Germing works mostly in the field of Myelodysplastic syndromes, limiting it down to concerns involving Leukemia and, occasionally, Survival rate.
His research investigates the connection with Oncology and areas like Cytogenetics which intersect with concerns in Karyotype. His Gastroenterology research is multidisciplinary, incorporating elements of Chemotherapy and Phases of clinical research. His work carried out in the field of Bone marrow brings together such families of science as CD34, Haematopoiesis and Cancer research.
Ulrich Germing spends much of his time researching Internal medicine, Myelodysplastic syndromes, Oncology, Myeloid leukemia and Lower risk. In his study, Salvage therapy is strongly linked to Azacitidine, which falls under the umbrella field of Internal medicine. In his study, which falls under the umbrella issue of Myelodysplastic syndromes, Retrospective cohort study is strongly linked to Survival rate.
His Oncology study also includes
His main research concerns Internal medicine, Myelodysplastic syndromes, Oncology, Myeloid leukemia and Lower risk. His Internal medicine study frequently links to related topics such as Azacitidine. His Myelodysplastic syndromes research is within the category of Bone marrow.
His work deals with themes such as Multivariate analysis, Immunology, Cause of death, Minimal residual disease and Neuroblastoma RAS viral oncogene homolog, which intersect with Oncology. His work in Myeloid leukemia addresses subjects such as Allogeneic transplantation, which are connected to disciplines such as Targeted therapy, Flt3 itd and Allo sct. His Lower risk study incorporates themes from Transfusion independence, Lenalidomide and Quality of life.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
Luca Malcovati;Ulrich Germing;Andrea Kuendgen;Matteo G. Della Porta.
Journal of Clinical Oncology (2007)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini.
Journal of Clinical Oncology (2010)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.
Detlef Haase;Ulrich Germing;Julie Schanz;Michael Pfeilstöcker.
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka;Richard F. Schlenk;Verena I. Gaidzik;Marianne Habdank.
Journal of Clinical Oncology (2010)
Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.
Stephanie Kruetzmann;M. Manuela Rosado;Holger Weber;Ulrich Germing.
Journal of Experimental Medicine (2003)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Peter Valent;Hans-Peter Horny;John M. Bennett;Christa Fonatsch.
Leukemia Research (2007)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Lübbert;Stefan Suciu;Liliana Baila;Björn Hans Rüter.
Journal of Clinical Oncology (2011)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati;Eva Hellström-Lindberg;David Bowen;Lionel Adès.
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo.
Journal of Clinical Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: